https://www.selleckchem.com/pr....oducts/nvp-bgt226.ht
02) when compared with PRP at 12 months. The difference in rates of vitrectomy and vitreous hemorrhage favoured anti-VEGF over PRP (risk difference [RD] -0.10, p = 0.001 and RD -0.10, p = 0.003 respectively). This meta-analysis of the available evidence in patients with early PDR demonstrates a potential benefit for anti-VEGF over PRP alone. However, these benefits must be weighed against the relative costs of treatment and the potential risks of loss to follow-up. This meta-analysis of the available evidence in patients with ea
Like
Comment
Share
